Featured Research

from universities, journals, and other organizations

Does Hormone Treatment Predispose Patients To Breast Cancer?

Date:
November 30, 2008
Source:
CNRS (Délégation Paris Michel-Ange)
Summary:
Breast cancer, the leading cause of death among women in France, is the most commonly occurring cancer in women. Sporadic breast cancer, which is non-hereditary, turns out to be the most widespread, representing 85 to 90% of all cases, but remains the least well-known. Researchers have just discovered the cause of 50% of sporadic breast cancers.

In the presence of AKT1 (green), BRCA1 (orange) is kept out of the nucleus (blue)
Credit: Copyright Laboratoire "Radiobiologie moléculaire et cellulaire"

Breast cancer, the leading cause of death among women in France, is the most commonly occurring cancer in women. Sporadic breast cancer, which is non-hereditary, turns out to be the most widespread, representing 85 to 90% of all cases, but remains the least well-known. Researchers at CNRS and CEA (1), working with a team from Hôpital Saint-Louis (2), have just discovered the cause of 50% of sporadic breast cancers.

The results should also explain epidemiological studies which suggest that hormone treatment predisposes patients to breast cancer. The work is published in 'Cancer Research'.

More than four out of five breast cancers are not related to hereditary factors. These cancers, which are called sporadic, are due to causes which were until recently considered complex and poorly understood. On the other hand, hereditary forms of cancer, which represent only 10 to 15% of breast cancers, have for years been the subjects of studies, work which has resulted in the identification of ten genes whose mutation increases the risk of cancer in an individual.

Among these genes, nine are involved in the DNA damage response system, which is the collection of cell mechanisms that optimize the repair of DNA. The tenth gene codes for a protein which inhibits the action of the AKT1 enzyme. And among these ten genes, two are responsible for 50% of hereditary breast cancers: BRCA1 and BRCA2. Researchers from the "Radiobiologie moléculaire et cellulaire" (CNRS / CEA) lab took these data on hereditary cancers as the starting point for their research into non-hereditary forms.

A link between hereditary and sporadic cancers It turns out that the AKT1 protein is over-expressed in 50% of sporadic breast cancers. Could this protein play a key role in predisposition to non hereditary breast cancer? The researchers, seeking an answer to this question, were able to show that activation of AKT1 leads to the sequestration of the BRCA1 protein in the cytoplasm. This makes it impossible for the protein to penetrate the nucleus, which prevents it from fulfilling its role in DNA repair. The cell then behaves as if it had no BRCA1 gene, without involving a mutation (unlike hereditary forms, where the BRCA1 gene undergoes an alteration). This phenomenon is observed in 50% of sporadic tumors. These results show a single, previously undetected, link between sporadic and hereditary cancers: the DNA damage response system.

The researchers have also suggested that hormone treatment may confer upon patients a predisposition to breast cancer. As AKT1 is activated by hormones, hormone treatment (3) could indeed, in some cases, result in the chronic activation of the molecule. If this is the case, it could lead to a deregulation of the BRCA1 gene, and, as a result, to breast cancer. These first results still need to be confirmed, something that the team led by Bernard Lopez (4) will do soon through further laboratory and clinical studies.

  1. Institut de radiobiologie cellulaire et moléculaire, which is part of the Department of Life Sciences.
  2. The team is led by Fabien Calvo, director of Inserm unit 716 "Cibles pharmacologiques dans les cancers"
  3. Like for example estrogen treatment.
  4. CNRS senior researcher and deputy director at the laboratory "Radiobiologie moléculaire et cellulaire"

Story Source:

The above story is based on materials provided by CNRS (Délégation Paris Michel-Ange). Note: Materials may be edited for content and length.


Cite This Page:

CNRS (Délégation Paris Michel-Ange). "Does Hormone Treatment Predispose Patients To Breast Cancer?." ScienceDaily. ScienceDaily, 30 November 2008. <www.sciencedaily.com/releases/2008/11/081121081059.htm>.
CNRS (Délégation Paris Michel-Ange). (2008, November 30). Does Hormone Treatment Predispose Patients To Breast Cancer?. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/11/081121081059.htm
CNRS (Délégation Paris Michel-Ange). "Does Hormone Treatment Predispose Patients To Breast Cancer?." ScienceDaily. www.sciencedaily.com/releases/2008/11/081121081059.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins